Duvyzat(Givinostat) Side Effects

Summary: Common adverse reactions include gastrointestinal disturbances, thrombocytopenia, and metabolic changes.  

Clinical and Trial-Observed Safety Profile  

Frequent adverse reactions (≥10% incidence) include diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), and pyrexia (13%). Less common events: rash (9%), arthralgia (8%), and hypothyroidism (5%). Severe cases of bleeding (e.g., epistaxis) and QTc prolongation were observed. 

Postmarketing data on long-term effects (e.g., carcinogenicity) are unavailable. Bone density reduction and neurobehavioral changes were noted in juvenile animal studies. Discontinuation rates in trials were low (2%), but dosage adjustments were frequent for thrombocytopenia (28%) and hypertriglyceridemia (8%). Persistent symptoms despite dose reduction necessitate permanent discontinuation.

Duvyzat(Givinostat)
Male patients aged 6 years and older with genetically confirmed DMD.
RELATED ARTICLES
Duvyzat's role and efficacy

Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD). It regulates gene...

Wednesday, July 16th, 2025, 17:10
/ 1
1 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved